You are here

Rapid Isolation of CDK4/Cyclin D Inhibitory Peptides

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1 R43 CA67502-01,
Agency Tracking Number: 29222
Amount: $100,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1995
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
One Kendall Square, Bldg 600
Cambridge, MA 02139
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Jeno Gyuris
 () -
Business Contact
Phone: () -
Research Institution
N/A
Abstract

Most human cancers carry molecular rearrangements of the critical apparatus that control cell divisinstances, two recently identified cell cycle inhibitors, p21/Waf1/Cip1 and p16/Ink4, failed to accunegative growth signals, leading to the uncontrolled proliferation characteristic of cancer cells. Dthis grant, our experimental work will focus on the development of a novel yeast genetic system whicidentification and characterization of short, hexameric peptide sequences that interact with Cdk4/Cyaction of p16/Ink4. Cancer cells in which the activity of the Cdk4/Cyclin D1 kinase is upregulated doverexpression or lack of p16/Ink4, remain exquisitely sensitive to the inhibition of Cyclin D1 funcantibody/antisense microinjection. In Phase II the inhibitory peptides will be further characterizedchemical modification to generate pharmacologically active derivatives. This research will lead to thighly specific antiproliferative agents.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government